Name | 6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-chromene-2-carboxylic acid |
---|---|
Synonyms |
rac-6-acetyl-7-<<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl>oxy>-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid
Ablukast 4-dihydro-2H-1-benzopyran-2-carboxylic acid Ablukastum 7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)-pentyloxy]-6-acetyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid 6-acetyl-7-<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyloxy>-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid UNII-000TKM5BBQ Ro-23-3544 Ablukast (USAN/INN) Ablukastum [INN-Latin] 7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)-pentyloxy]-6-acetyl-3 |
Description | Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction[1][2]. Ablukast is LTD4 receptor antagonist[3]. |
---|---|
Related Catalog | |
Target |
LTD4 |
In Vitro | Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation[2]. |
In Vivo | Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation[2]. Animal Model: Female BALB/c mice[2] Dosage: Concentrations of 0.1 , 0.5 , 1.0 and 5.0 % of Ablukast Administration: Applied to one of the pretreated ears 1 h after elicitation and at 24 h intervals on the following 4 days; three times daily Result: Effectively reduced DNFB-induced ear swelling. |
References |
Density | 1.219g/cm3 |
---|---|
Boiling Point | 730.8ºC at 760mmHg |
Molecular Formula | C28H34O8 |
Molecular Weight | 498.56500 |
Flash Point | 240.9ºC |
Exact Mass | 498.22500 |
PSA | 119.36000 |
LogP | 5.15620 |
Index of Refraction | 1.567 |
Precursor 9 | |
---|---|
DownStream 0 |